Who Paid My Doc
Nick Vatakis
New York, NY Medical Doctor
NPI 1285835637 CMS profile 1379204
150 E 69Th St, Suite 2H, New York, NY 10021
General payments
$0
Research payments
$4,711
Ownership & investment interest
$0
Research they led as principal investigator
$5,580,447
Through program year 2025, Nick Vatakis of New York, NY is reported in the CMS Open Payments database as having received $0 across 0 general payments and $4,711 in research payments paid to them. Separately, studies naming them as principal investigator received $5,580,447 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $3,200 | 1 | |
| 2023 | Research | $300 | 1 | |
| 2019 | Research | $1,211 | 7 |
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
416
Drug cost
$44,431
Branded share of claims
22.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rexulti Brexpiprazole | Brand | 21 | $32,687 | |
| Klonopin Clonazepam | Brand | 20 | $3,689 | |
| Lamotrigine Er Lamotrigine | Brand | 12 | $2,301 | |
| Bupropion Xl Bupropion Hcl | Brand | 27 | $939 | |
| Lamotrigine | Generic | 28 | $845 | |
| Clonazepam | Generic | 68 | $811 | |
| Lurasidone Hcl | Generic | 21 | $782 | |
| Bupropion Hcl Sr Bupropion Hcl | Brand | 12 | $580 | |
| Escitalopram Oxalate | Generic | 19 | $379 | |
| Trazodone Hcl | Generic | 41 | $315 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Records
9 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.